During the past decade, Snake River Research, PLLC conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 5 clinical trials were completed, i.e. on average, 21.7% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 5 clinical trials were completed. i.e. 29.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Snake River Research, PLLC" #1 sponsor was "Pfizer" with 6 trials, followed by "Janssen Research & Development, LLC" with 3 trials sponsored, "Actelion" with 1 trials sponsored, "Aerpio Therapeutics" with 1 trials sponsored and "Bavarian Nordic" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Snake River Research, PLLC" #1 collaborator was "Department of Health and Human Services" with 1 trials as a collaborator, "Medical Technology Enterprise Consortium (MTEC)" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 1 trials as a collaborator and "Pharm-Olam International" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Snake River Research, PLLC" are "Clostridium Difficile Infection" (4 trials), "COVID-19" (3 trials), "Clostridioides Difficile Infection" (2 trials), "Covid19" (2 trials) and "Acute Respiratory Distress Syndrome" (1 trials). Many other conditions were trialed in "Snake River Research, PLLC" in a lesser frequency.

Most popular intervention types in "Snake River Research, PLLC" are "Drug" (13 trials), "Biological" (9 trials), "Other" (4 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "13-valent pneumococcal conjugate vaccine" (1 trials), "20-valent pneumococcal conjugate vaccine" (1 trials), "Active Comparator" (1 trials) and "Apixaban 2.5 MG" (1 trials). Other intervention names were less common.

The vast majority of trials in "Snake River Research, PLLC" are 22 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Snake River Research, PLLC". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Snake River Research, PLLC, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Snake River Research, PLLC, 2 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".